Ianalumab, Ibrutinib Combination Promising in Chronic Lymphocytic Leukemia
Researchers sought to determine whether combination therapy with ianalumab and ibrutinib would have efficacy in patients with CLL.
Diagnosis & Disease Information
Improving Risk Stratification in Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia in Children
Researchers sought to better discriminate true MRD positivity for risk stratification in chronic lymphocytic leukemia and acute lymphoblastic leukemia in children.
Fixed Venetoclax Dosing May Not Be Feasible for All Patients With CLL
Researchers sought to determine whether patients with CLL/SLL would be able to maintain fixed dosing schedule of venetoclax-based regimens in their treatments.
Exercise Alters T-Cell Ratio and Improves Physical Functioning in CLL
Researchers sought to determine the impact of exercise done at home by patients with chronic lymphocytic leukemia.
Trial Evaluating Lisocabtagene Maraleucel for Relapsed/Refractory CLL Meets Endpoint
Lisocabtagene maraleucel is a CD19-directed genetically modified autologous T cell immunotherapy.
Brukinsa Gains Approval for Chronic Lymphocytic Leukemia
The approval was based on data from the phase 3 SEQUOIA and ALPINE studies in patients with CLL/SLL.
Zanubrutinib Outperforms Ibrutinib in Relapsed/Refractory CLL/SLL
Zanubrutinib prolongs progression-free survival, when compared with ibrutinib, in patients with relapsed/refractory CLL/SLL, a phase 3 trial suggests.
Chronic Lymphocytic Leukemia Updates Presented at the 2022 ASH Annual Meeting
Research in patients with CLL showed that zanubrutinib can outperform ibrutinib, a triplet is effective for high-risk CLL, cell death may predict the depth of response, and a CAR T-cell therapy is likely not an option for CLL patients.
MRD-Guided Treatment Intensification Feasible in R/R Chronic Lymphocytic Leukemia
Researchers sought to determine whether uMRD could determine discontinuation of venetoclax or the addition of ibrutinib in patients with R/R CLL.
Addition of Anti-CD19 CAR-T to Ibrutinib Yields Deep, Durable Remissions in Chronic Lymphocytic Leukemia
Researchers sought to determine whether adding anti-CD19 CAR-T cells to ibrutinib would improve remission rates in CLL.
- Loading...
Loading...
Next post in Leukemia
Loading... 
Loading...